Señales en vivo de 4597.T | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (30 abr 2024 @ 02:15):

Stats
Volumen de hoy	954 300
Volumen promedio	3.29M
Capitalización de mercado	5.01B
EPS	¥0 ( 2024-02-14 )
Próxima fecha de ganancias	( ¥0 ) 2024-05-12
Last Dividend	¥0 ( N/A )
Next Dividend	¥0 ( N/A )
P/E	-3.93
ATR14	¥0.159 (0.61%)

Volumen Correlación

Largo: 0.13 (neutral)

Corto: -0.22 (neutral)

Signal:(48.14) Neutral

Solasia Pharma K.K. Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Solasia Pharma K.K. Correlación - Moneda/Commodity

-0.08
( neutral )

0.15
( neutral )

0.31
( neutral )

0.16
( neutral )

-0.24
( neutral )

-0.09
( neutral )

Solasia Pharma K.K. Finanzas

Annual	2023
Ingresos:	¥617.00M
Beneficio Bruto:	¥-163.00M (-26.42 %)
EPS:	¥-6.61

FY	2023
Ingresos:	¥617.00M
Beneficio Bruto:	¥-163.00M (-26.42 %)
EPS:	¥-6.61

FY	2022
Ingresos:	¥1.09B
Beneficio Bruto:	¥662.00M (60.62 %)
EPS:	¥-16.76

FY	2021
Ingresos:	¥559.00M
Beneficio Bruto:	¥374.00M (66.91 %)
EPS:	¥-19.04

Financial Reports:

No articles found.

Solasia Pharma K.K.

Solasia Pharma K.K. develops and commercializes drugs in the field of oncology in Japan and other Asian countries. The company offers SP-03 (episil oral liquid) for the protection and relief of oral pain associated with oral mucositis/stomatitis caused by chemotherapy and radiotherapy for cancer; and SP-01 (Sancuso), a transdermal delivery system that delivers granisetron, an anti-emetic into the patient's bloodstream for the treatment of chemotherapy induced nausea and vomiting. It is also developing SP-02 (Darinaparsin), a mitochondrial-targeted agent that has completed phase III clinical study to treat various hematologic and solid cancers; and SP-04 a chemotherapy induced peripheral neuropathy which is in pre-clinical stage. In addition, the company is developing SP-05 (Arfolitixorin) that is in phase III clinical study for the enhancement of antitumor efficacy of fluorouracil, including the treatment for pancreatic cancer, breast cancer, stomach cancer, and head and neck cancers. Solasia Pharma K.K. was founded in 2006 and is based in Tokyo, Japan.